A temporary shortage of FDA-approved GLP-1 drugs opened the door to a flood of unapproved knock-offs from compounding pharmacies looking to cash in. The shortage has ended, but some compounders continue to mass-produce the drugs. Below are some myths mass compounders continue to use to justify their illegal actions
—and corresponding facts that policymakers, providers, and the public should know to keep patients safe.
READ FULL REPORT HERE
